NEWS

Healthcare costs continue to be a significant concern for Americans. While policies like government price controls under the Inflation...

Small-molecule drugs, which typically come in pill or tablet form, have long been the backbone of modern medicine, treating everything...

Research firm Vital Transformation is preparing a new analysis about the impacts of the Inflation Reduction Act on biopharma investment,...

At We Work For Health (WWFH), our commitment to fostering health equity across the nation goes beyond advocacy—it extends to tangible,...

The biopharmaceutical industry is the backbone of America's innovative economy, supporting more than 4.9 million jobs across the United...

As Congress returned to Washington, the Senate Judiciary Committee held a full committee hearing  to consider a number of critical bills...

New research from the IQVIA Institute for Human Data Science further confirms what We Work For Health (WWFH) and others have warned...

The Drug Price Competition and Patent Term Restoration Act, more commonly known as the Hatch-Waxman Act, profoundly changed the...

As healthcare access and costs continue to dominate political conversations, the flaws in the Inflation Reduction Act are becoming...

In 1984, the Hatch-Waxman Act – formally known as the bipartisan Drug Price Competition and Patent Term Restoration Act  – established a...

During a recent We Work For Health roundtable with California Rep. Scott Peters, leaders across patient advocacy, biopharma, labor,...

American innovation depends on a strong, robust intellectual property system that allows health care advances to save and enhance lives....